PCI Biotech to present poster at the ESMO Symposium on Immuno-Oncology 2016

Oslo, November 4, 2016 – PCI Biotech will present a poster at the European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology 2016. This 4th ESMO Symposium on Immuno-Oncology will take place in Lausanne, Switzerland; 4-6 November 2016. The company will be represented by Dr. Anders Høgset, Chief Scientific Officer. The poster is named “Clinical validation of Photochemical internalisation (fimaVACC) – a novel technology for enhancing cellular immune responses to peptide- and protein-based therapeutic cancer vaccines”, and is available below.pci-biotech-poster-at-esmo-immuno-oncology-2016

About the ESMO Symposium on Immuno-Oncology 2016

This symposium underlines ESMO’s commitment to educate cancer physicians and researchers in a rapidly evolving area of treating cancer through immunotherapy. The symposium will offer an update on the latest developments in immuno-oncology in an effort to bring innovative approaches directly to patients.

About PCI Biotech

PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429